$DH

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.

Definitive Healthcare Corp. (DH) named Clay Ritchey as CEO and board member, effective September 8. Ritchey succeeds Kevin Coop, who left on August 31, 2026. Ritchey previously led Verato, Evariant, and other healthcare firms. DH shares rose 13.04% in pre-market trading.

Definitive Healthcare (NASDAQ:DH) shares rose 13% after Advent International offered to buy the company for $1.02 per share, a 36% premium over its 60-day average. The deal requires approval from a special committee and Jason Krantz's stock rollover. Definitive Healthcare also appointed Clay Ritchey as CEO, replacing Kevin Coop.

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Definitive Healthcare Appoints Clay Ritchey as CEO Mr. Ritchey brings more than 25 years of deep healthcare expertise to Definitive Framingham, MA (September 2, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthca

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

Definitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.

Definitive Healthcare announced a significant expansion of its prescription and all-payor medical claims data within the Atlas Dataset, increasing coverage by over 60% for prescription claims and considerably for all-payor claims, including a nearly 20% rise in key areas like rare disease and oncology. This expansion, coupled with refined methodologies and increased patient overlap, provides clients with a more in-depth and holistic view of patient journeys to better understand market trends, inform product development, and optimize go-to-market strategies. The enhanced data aims to accelerate commercial success for organizations partnering with healthcare providers.

Definitive Healthcare (DH) delivered earnings and revenue surprises of +16.67% and +1.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?